Proteomic analysis of plasma in healthy adults receiving recombinant vaccinia virus provides novel insights into HIV‐1 neutralizing antibodies
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Ran Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese…. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Vaccinia virus, HIV Antibodies, HIV-1. Die Arbeit nennt 47 Literaturangaben. Gefördert von: The National Natural Science Foundation of China for the project "Mechanisms of Follicular Helper T Cells in Regulating HIV-1 Specificity and Antibody Maturati…, The Youth Fund of the Chinese Center for Disease Control and Prevention, Grant/Award Number: 2022A105, The Major National Science and Technology Projects of China for "AIDS Vaccine Research", Grant/Award Number: 2018ZX10731-101.
Abstract (Originalsprache)
Human immunodeficiency virus (HIV) infection is still a global public health issue, and the development of an effective prophylactic vaccine inducing potent neutralizing antibodies remains a significant challenge. This study aims to explore the inflammation‐related proteins associated with the neutralizing antibodies induced by the DNA/rTV vaccine. In this study, we employed the Olink chip to analyze the inflammation‐related proteins in plasma in healthy individuals receiving HIV candidate vaccine (DNA priming and recombinant vaccinia virus rTV boosting) and compared the differences between neutralizing antibody‐positive (nab + ) and –negative(nab‐) groups. We identified 25 differentially expressed factors and conducted enrichment and correlation analysis on them. Our results revealed that significant expression differences in artemin (ARTN) and C‐C motif chemokine ligand 23 (CCL23) between nab+ and –nab‐ groups. Notably, the expression of CCL23 was negatively corelated to the ID 50 of neutralizing antibodies and the intensity of the CD4 + T cell responses. This study enriches our understanding of the immune picture induced by the DNA/rTV vaccine, and provides insights for future HIV vaccine development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
- Changping Laboratory, Beijing, China.
ORCID-Profile: Ran Chen
Förderung
- The National Natural Science Foundation of China for the project "Mechanisms of Follicular Helper T Cells in Regulating HIV-1 Specificity and Antibody Maturati…
- The Youth Fund of the Chinese Center for Disease Control and Prevention, Grant/Award Number: 2022A105
- The Major National Science and Technology Projects of China for "AIDS Vaccine Research", Grant/Award Number: 2018ZX10731-101
Zitieren
APA
Chen, R., Fu, Y., Li, D., Wang, S., Ruan, Y., Ren, L., Wang, S., Shen, X., Shi, Y., Shao, Y., & Liu, Y. (2024). Proteomic analysis of plasma in healthy adults receiving recombinant vaccinia virus provides novel insights into HIV‐1 neutralizing antibodies. Journal of Medical Virology. https://doi.org/10.1002/jmv.29749
Vancouver
Chen R, Fu Y, Li D, Wang S, Ruan Y, Ren L, et al. Proteomic analysis of plasma in healthy adults receiving recombinant vaccinia virus provides novel insights into HIV‐1 neutralizing antibodies. Journal of Medical Virology. 2024. doi:10.1002/jmv.29749
BibTeX
@article{Chen2024,
author = {Chen, Ran and Fu, Yuyu and Li, Dan and Wang, Shuhui and Ruan, Yuhua and Ren, Li and Wang, Shuo and Shen, Xiuli and Shi, Yutao and Shao, Yiming and Liu, Ying},
title = {Proteomic analysis of plasma in healthy adults receiving recombinant vaccinia virus provides novel insights into HIV‐1 neutralizing antibodies},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29749}
}
EUVIMED